NCT00197132已完成3 期
A Single-centre, Randomised, Double-blind, Placebo Controlled, Two 12 Week Period, Cross-over Phase III Study to Investigate the Effect of Rosiglitazone 4mg bd on the Vasodilator Response to Hyperinsulinaemia in Obese Insulin Resistant Subjects.
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 2
- 主要终点
- Forearm blood flow
研究概览
简要总结
Fluid management study in patients with insulin resistance.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 30 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •BMI 27-36 kg/m2 inclusive and at least two additional features of the metabolic syndrome or a first degree relative with a history of type 2 diabetes mellitus. BMI = Weight/height², (where weight is in kg, height in m).
- •Male or female aged 30 to 65 years, inclusive, at screening.
- •Female subjects must be post-menopausal (i.e. >6 months without menstrual period), surgically sterile, or using effective contraceptive measures (oral contraceptives, Norplant Depo-Provera) or intra-uterine devices (IUD) (a diaphragm with spermicide or a condom with spermicide). Women of childbearing potential must use effective contraceptive measures for at least 1 month prior to visit 1, and should continue to use the same contraceptive method during the study and for 30 days after discontinuing study treatment.
- •Willing and able to provide a signed and dated written informed consent.
排除标准
- •Subjects with type 2 diabetes mellitus defined as an HbA1c level >6.5% or a fasting plasma glucose of > 7.0 mmol/L. If fasting plasma glucose is between 6.1 and 7.0 mmol/L then a 75 g oral glucose test will be performed to exclude diabetes mellitus.
- •Subjects who have initiated lipid lowering therapy within the last 6 months and subjects who have increased the dose of these therapies within the last 3 months prior to study start.
- •Subjects who are taking Non Steroidal Anti-inflammatory Drugs, fibrates, anticoagulants or cardiovascular medications (β-blockers, nitrates, calcium antagonists, ACE inhibitors, angiotensin II antagonists, alpha blockers, diuretics, centrally acting anti-hypertensives, directly acting antihypertensives e.g., diazoxide, digoxin, anti-arrhythmics) and are unable to stop these medications for the duration of the study.
- •Exposure to a thiazolidinedione (TZD) or other PPAR-γ agonist (e.g. rosiglitazone, troglitazone, pioglitazone, G1262570) within the last 4 months or participation in a clinical study involving a TZD or PPAR-γ agonist.
- •Subjects who have required the use of any anti-diabetic medication at any time.
- •Use of any investigational drug within 30 days preceding the first dose of medication at the start of the study.
- •Subjects with a documented history of significant hypersensitivity (e.g. difficulty swallowing, difficulty breathing, tachycardia or skin reaction) to thiazolidinediones or PPAR-γ agonists.
- •Systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg or receiving antihypertensive therapy.
- •Subjects with unstable or severe angina (requiring continual therapy) or congestive heart failure.
- •Presence of clinically significant hepatic disease.
- •Clinically significant anaemia.
- •Subjects with creatinine clearance <40 mL/min.
- •Women who are lactating, pregnant or planning to become pregnant during the course of the study.
- •Alcohol or drug abuse within the last 6 months.
结局指标
主要结局
Forearm blood flow
次要结局
- Insulin sensitivity, plasma volume, transcapillary escape rate, inhibition to vasodialtory response, changes in cardiac output, plasma catecholamine levels, changes in plasma hormone/markers of vascular permeability, safety and tolerability.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Fluid Retention in Rosiglitazone Treated Subjects With Autonomic Neuropathy.Neuropathy, DiabeticNCT00422955GlaxoSmithKline36
招募中
不适用
Case control study of insulin resistance and metabolic syndrome in pimples among men of age more than 20CTRI/2018/03/012532K S Hegde medical academy
招募中
不适用
A study on insulin technique of diabetic patientsdiabetes mellitusJPRN-UMIN000033698Takagi Hospital50
已完成
3 期
A placebo-controlled trial of insulin therapy with or without adjuvant metformin in patients with Cystic Fibrosis-Related Diabetes10038686Cystic Fibrosis10018424NL-OMON38078HagaZiekenhuis25
进行中（未招募）
不适用
A placebo-controlled trial of insulin therapy with or without adjuvant metformin in patients with cystic fibrosis-related diabetes - Insulin therapy and adjuvant metformin in CFRDCystic fibrosis-related diabetesMedDRA version: 9.1Level: HLTClassification code 10012602Term: Diabetes mellitus (incl subtypes)MedDRA version: 9.1Level: LLTClassification code 10011762Term: Cystic fibrosisEUCTR2009-009875-37-NLStaf Longziekten25